IGC Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IGC Pharma and other ETFs, options, and stocks.About IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development.
CEORam Mukunda
CEORam Mukunda
Employees70
Employees70
HeadquartersPotomac, Maryland
HeadquartersPotomac, Maryland
Founded2005
Founded2005
Employees70
Employees70
IGC Key Statistics
Market cap26.95M
Market cap26.95M
Price-Earnings ratio-3.74
Price-Earnings ratio-3.74
Dividend yield—
Dividend yield—
Average volume965.84K
Average volume965.84K
High today$0.2999
High today$0.2999
Low today$0.276
Low today$0.276
Open price$0.28
Open price$0.28
Volume403.48K
Volume403.48K
52 Week high$0.4985
52 Week high$0.4985
52 Week low$0.2525
52 Week low$0.2525
Stock Snapshot
With a market cap of 26.95M, IGC Pharma(IGC) trades at $0.28. The stock has a price-to-earnings ratio of -3.74.
During the trading session on 2026-01-04, IGC Pharma(IGC) shares reached a daily high of $0.30 and a low of $0.28. At a current price of $0.28, the stock is +2.2% higher than the low and still -6.0% under the high.
Trading volume for IGC Pharma(IGC) stock has reached 403.48K, versus its average volume of 965.84K.
The stock's 52-week range extends from a low of $0.25 to a high of $0.50.
The stock's 52-week range extends from a low of $0.25 to a high of $0.50.
IGC News
TipRanks 2d
IGC Pharma Adjusts Fiscal Year-End to December 31Claim 70% Off TipRanks This Holiday Season IGC Pharma ( (IGC) ) has provided an announcement. On December 30, 2025, IGC Pharma, Inc. announced that its Board...
People also own
Based on the portfolios of people who own IGC. This list is generated using Robinhood data, and it’s not a recommendation.